Bristol-Myers Squibb Services Unlimited Company — Sponsor Intelligence | 87 EU Trials

Filter these 87 trials by condition, phase, country and more.

Open in Search →

87 Registered trials

43 Recruiting

37 Completed trials

22 Countries active

84 Unique IMPs

100% Results reported

Phase III

Phase II/III

Phase II

Phase III: 44 Phase II/III: 9 Phase II: 11 Phase I/II: 4 Phase III/IV: 1 Phase I: 4 Phase I (Other): 6 Phase I (FiH): 8

Oversight events:

14 temporary halts 2 unexpected events 4 corrective measures across 10 trials

View oversight register →

100%

37 of 37 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Non-small cell lung cancer 6 Dementia Alzheimer's type 6 Non-small cell lung cancer metastatic 5 Mania 4 Non-small cell lung cancer recurrent 3 Systemic lupus erythematosus 3 Subacute cutaneous lupus erythematosus 2 Schizophrenia 2 Rheumatoid arthritis 2 Hepatocellular carcinoma 2 Idiopathic pulmonary fibrosis 1 Metastatic renal cell carcinoma 1

Top IMPs

NIVOLUMAB 22 TROSPIUM CHLORIDE, XANOMELINE TARTRATE 12 DEUCRAVACITINIB 11 IPILIMUMAB 8 NIVOLUMAB, RELATLIMAB 6 XANOMELINE TARTRATE 6 PUMITAMIG 5 IZALONTAMAB BRENGITECAN 4 2-[4-[4-(AMINOMETHYL)-1-OXO-2H-PHTHALAZIN-6-YL]-2-METHYLPYRAZOL-3-YL]-4-CHLORO-6-CYCLOPROPYLOXY-3-FLUOROBENZONITRILE 3 CISPLATIN 3 ADMILPARANT 2 BEVACIZUMAB 2

All trials — page 2

87 total

A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors Recruiting

2025-524334-26-01 Phase I 1 country
A Phase 1/1b First-in-Human Study of BMS-986506 in ccRCC Recruiting

2025-522543-18-00 Phase I 2 countries
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer with Disease Progression on or Af… Recruiting

2025-522400-24-00 Phase II/III 11 countries IZALONTAMAB BRENGITECAN
Efficacy and Safety of Lisocabtagene Maraleucel (liso-cel) as First-Line Therapy in Adults with Transplant-Ineligible Primary Central Nervou… Recruiting

2025-521144-38-00 Phase II 2 countries LISOCABTAGENE MARALEUCEL
A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants with Advanced Solid Tumors Recruiting

2025-522203-23-00 Phase I (FiH) 2 countries BMS-986517
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated with Alzheimer’s Disease. Recruiting

2025-520612-34-00 Phase III 5 countries TROSPIUM CHLORIDE, XANOMELINE TARTRATE; XANOMELINE TARTRATE
A Phase 1/2 Study of BMS-986482 Alone or Combination Therapy in Participants with Advanced Solid Tumors Recruiting

2024-516602-28-00 Phase I (FiH) 8 countries BMS-986482; NIVOLUMAB; NIVOLUMAB, RELATLIMAB
A Study of BMS-986504 in Combination with Pembrolizumab Plus Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line M… Recruiting

2025-521511-40-00 Phase II/III 15 countries 2-[4-[4-(AMINOMETHYL)-1-OXO-2H-PHTHALAZIN-6-YL]-2-METHYLPYRAZOL-3-YL]-4-CHLORO-6…
Study of Izalontamab Brengitecan (BMS-986507) versus Treatment of Physician’s Choice in Patients with Previously Untreated, Locally Advanced… Recruiting

2024-519871-24-00 Phase II/III 10 countries IZALONTAMAB BRENGITECAN
A Phase 3 Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder Recruiting

2024-520165-32-00 Phase III 3 countries TROSPIUM CHLORIDE, XANOMELINE TARTRATE
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated with Alzheimer’s Disease. Recruiting

2025-520613-31-00 Phase III 6 countries TROSPIUM CHLORIDE, XANOMELINE TARTRATE; XANOMELINE TARTRATE
A Phase 3 Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer’s Disease Recruiting

2025-520747-32-00 Phase III 10 countries TROSPIUM CHLORIDE, XANOMELINE TARTRATE; XANOMELINE TARTRATE
A Phase 3 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Deucravacitinib (BMS-986165) in Adolescent Participants with Moder… Recruiting

2023-506296-97-00 Phase III 7 countries DEUCRAVACITINIB
A Study of Navlimetostat (BMS986504) in Participants with Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer with Homozygous MTAP… Recruiting

2024-519814-29-00 Phase II 7 countries 2-[4-[4-(AMINOMETHYL)-1-OXO-2H-PHTHALAZIN-6-YL]-2-METHYLPYRAZOL-3-YL]-4-CHLORO-6…
A Phase 1 Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants with Severe, Refractory Autoimmune Diseases Recruiting

2024-517681-41-00 Phase I 6 countries
A Study of Nivolumab + Relatlimab Fixed-dose Combination with Chemotherapy Versus Pembrolizumab with Chemotherapy in Participants with Non-s… Recruiting

2024-513682-40-01 Phase III 12 countries NIVOLUMAB, RELATLIMAB
A Phase 1/2a Study of BMS-986507 (BL-B01D1) in Adult Participants with Advanced Solid Tumors Recruiting

2024-514947-27-00 Phase I/II 4 countries IZALONTAMAB BRENGITECAN
A Phase 1/2a, First-in-human Study to Evaluate BMS-986470 in Healthy Volunteers and Participants with Sickle Cell Disease Recruiting

2023-510283-12-00 Phase I (FiH) 1 country BMS-986470
Study of Adagrasib plus Pembrolizumab plus Chemotherapy vs. Placebo plus Pembrolizumab plus Chemotherapy in Participants with Previously Unt… Recruiting

2024-515698-85-00 Phase III 15 countries ADAGRASIB
A Phase 3, Parallel Group Study to Evaluate KarXT as a Treatment for Psychosis Associated with Alzheimer’s Disease Recruiting

2024-516363-92-00 Phase III 13 countries TROSPIUM CHLORIDE, XANOMELINE TARTRATE
[14C]-BMS986504 Mass Balance Study in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion Recruiting

2024-515518-41-00 Phase I (Other) 2 countries
A Phase 3 Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants with Juveni… Recruiting

2024-517262-41-00 Phase III 6 countries DEUCRAVACITINIB
Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults with Active Sjögren’s Syndrome Recruiting

2023-503327-26-00 Phase III 15 countries DEUCRAVACITINIB
A Study of Subcutaneous Nivolumab + Relatlimab FDC in Previously Untreated Metastatic or Unresectable Melanoma (RELATIVITY-127) Recruiting

2022-500967-11-00 Phase III 11 countries NIVOLUMAB, RELATLIMAB

Showing 25–48 of 87 trials

← All sponsors A–Z